ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 123 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,157,823 | -96.9% | 57,718 | -95.6% | 0.00% | -100.0% |
Q2 2023 | $37,277,681 | +68.0% | 1,321,435 | +2.4% | 0.02% | +50.0% |
Q1 2023 | $22,193,091 | -19.3% | 1,290,296 | -5.5% | 0.01% | -16.7% |
Q4 2022 | $27,501,130 | -4.7% | 1,365,498 | +2.5% | 0.01% | -14.3% |
Q3 2022 | $28,849,000 | -24.2% | 1,331,884 | -1.7% | 0.01% | -17.6% |
Q2 2022 | $38,060,000 | -17.2% | 1,354,463 | +35.9% | 0.02% | -5.6% |
Q1 2022 | $45,990,000 | -41.0% | 996,759 | +7.5% | 0.02% | -35.7% |
Q4 2021 | $77,918,000 | +18.6% | 926,937 | -6.0% | 0.03% | +7.7% |
Q3 2021 | $65,704,000 | +31.3% | 985,953 | +4.8% | 0.03% | +30.0% |
Q2 2021 | $50,052,000 | +4.4% | 940,828 | -14.9% | 0.02% | -4.8% |
Q1 2021 | $47,958,000 | +10.7% | 1,105,282 | +32.5% | 0.02% | +5.0% |
Q4 2020 | $43,341,000 | +72.0% | 834,448 | +8.3% | 0.02% | +42.9% |
Q3 2020 | $25,196,000 | +5.3% | 770,770 | +54.7% | 0.01% | 0.0% |
Q2 2020 | $23,927,000 | – | 498,272 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |